Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Express Scripts
Moodys
Medtronic
AstraZeneca
Baxter
McKinsey

Last Updated: February 9, 2023

Details for Patent: 7,795,312


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Summary for Patent: 7,795,312
Title:Method for treating abdominal discomfort
Abstract:A method for treating irritable bowel syndrome in a mammalian subject includes administering an effective amount of 13,14-dihydro-15-keto-16,16-difluoro-18-methyl-prostaglandin E.sub.1 or 13,14-dihydro-15-keto-16,16-difluoro-prostaglandin E.sub.1, or a salt, ether, ester or amide thereof, to the subject. A method for treating abdominal discomfort associated with irritable bowel syndrome in a mammalian subject includes administering an effective amount of 13,14-dihydro-15-keto-16,16-difluoro-18-methyl-prostaglandin E.sub.1 or 13,14-dihydro-15-keto-16,16-difluoro-prostaglandin E.sub.1, or a salt, ether, ester or amide thereof, to the subject.
Inventor(s): Ueno; Ryuji (Montgomery, MD), Kuno; Sachiko (Montgomery, MD)
Assignee: Sucampo AG (Zug, CH)
Application Number:10/745,689
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,795,312
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 7,795,312

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Sucampo Pharma Llc AMITIZA lubiprostone CAPSULE;ORAL 021908-002 Apr 29, 2008 AB RX Yes No See Plans and Pricing See Plans and Pricing METHOD FOR TREATING IRRITABLE BOWEL SYNDROME AND METHOD FOR TREATING ABDOMINAL DISCOMFORT ASSOCIATED WITH IRRITABLE BOWEL SYNDROME See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 7,795,312

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 042670 See Plans and Pricing
Argentina 106393 See Plans and Pricing
Australia 2003292556 See Plans and Pricing
Brazil 0317740 See Plans and Pricing
Brazil PI0317740 See Plans and Pricing
Canada 2510051 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
Merck
Johnson and Johnson
Mallinckrodt
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.